CLIN CANCER RES:miRNA特征进行结直肠癌复发预测

2018-08-29 MedSci MedSci原创

目前使用的TNM分期系统不能充分鉴别出高风险的结直肠癌患者。CLIN CANCER RES近期发表了一篇文章,寻找优于目前TNM分期及常用的分子标志的miRNA复发分层(MRC)系统。

目前使用的TNM分期系统不能充分鉴别出高风险的直肠癌患者。CLIN CANCER RES近期发表了一篇文章,寻找优于目前TNM分期及常用的分子标志的miRNA复发分层(MRC)系统。

作者使用三个独立的miRNA表达数据集寻找并验证可以预测结直肠肿瘤患者复发的miRNA特征。后续在独立的患者队列中使用这一特征进行训练并验证。最终作者发现了一种8-miRNA特征,可以在发现队列及两个独立的公共数据集中有效预测无复发间期(RFI)。在独立的临床队列中进行的RT-PCR为基础的验证表明,MRC判断的高风险患者无复发间期更差。多因素分析表明,MRC是肿瘤复发的独立预测因素,且比现有的分子标志预测效果更好。MRC风险评分=(-0.1218×miR-744)+(-3.7142×miR-429)+(-2.2051×miR-362)+(3.0564×miR-200b)+(2.4997×miR-191)+(-0.0065×miR-30c2)+(2.2224×miR-30b)+(-1.1162×miR-33a)。

文章最后认为,该MRC优于现有的临床病理特征,可以有效鉴别高风险Ⅱ期或Ⅲ期直肠癌患者,且与患者是否接受辅助化疗无关。可以在临床中进行应用以进一步测试和验证该模型。

原始出处:
Raju Kandimalla,Feng Gao,et al.Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage Ⅱand Ⅲ Colorectal Cancer.CLIN CANCER RES.August 2018 doi:10.1158/1078-0432.CCR-17-3236

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1930640, encodeId=9302193064043, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon May 20 10:14:00 CST 2019, time=2019-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312352, encodeId=7ff013123526b, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Fri Aug 31 11:14:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453151, encodeId=e10514531519e, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Fri Aug 31 11:14:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341735, encodeId=7ae7341e355e, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Aug 30 08:06:30 CST 2018, time=2018-08-30, status=1, ipAttribution=)]
    2019-05-20 smallant2002
  2. [GetPortalCommentsPageByObjectIdResponse(id=1930640, encodeId=9302193064043, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon May 20 10:14:00 CST 2019, time=2019-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312352, encodeId=7ff013123526b, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Fri Aug 31 11:14:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453151, encodeId=e10514531519e, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Fri Aug 31 11:14:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341735, encodeId=7ae7341e355e, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Aug 30 08:06:30 CST 2018, time=2018-08-30, status=1, ipAttribution=)]
    2018-08-31 Homburg
  3. [GetPortalCommentsPageByObjectIdResponse(id=1930640, encodeId=9302193064043, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon May 20 10:14:00 CST 2019, time=2019-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312352, encodeId=7ff013123526b, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Fri Aug 31 11:14:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453151, encodeId=e10514531519e, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Fri Aug 31 11:14:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341735, encodeId=7ae7341e355e, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Aug 30 08:06:30 CST 2018, time=2018-08-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1930640, encodeId=9302193064043, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Mon May 20 10:14:00 CST 2019, time=2019-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312352, encodeId=7ff013123526b, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Fri Aug 31 11:14:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453151, encodeId=e10514531519e, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Fri Aug 31 11:14:00 CST 2018, time=2018-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=341735, encodeId=7ae7341e355e, content=了解一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Aug 30 08:06:30 CST 2018, time=2018-08-30, status=1, ipAttribution=)]
    2018-08-30 kafei

    了解一下谢谢

    0

相关资讯

ANN ONCOL:转移性结直肠癌原发肿瘤部位与FOLFOXIRI联合贝伐单抗治疗获益的关系

右侧转移性结直肠癌患者预后较差,接受一线化疗联合靶向治疗的临床获益有限。ANN ONCOL近期发表了一篇文章,研究转移性结直肠癌患者原发肿瘤部位的预后及预测作用,根据原发肿瘤部位及RAS和BRAF突变状态进行亚组分析。

ANN ONCOL:替莫唑胺联合伊立替康治疗携带MGMT甲基化的晚期结直肠癌患者

非随机性研究表明替莫唑胺治疗携带MGMT甲基化的转移性结直肠癌患者缓解率可达到10%。ANN ONCOL近期发表了一篇文章,评估伊立替康联合替莫唑胺(TEMIRI)治疗伊立替康敏感,MGMT甲基化/微卫星灶稳定(MSS)的接受过其他治疗的转移性结直肠癌患者的疗效

2018 CAG临床实践指南:非遗传性结直肠癌和腺瘤家族史个体结直肠癌筛查

2018年8月,加拿大胃肠病学协会(CAG)发布了非遗传性结直肠癌会腺瘤家族史个体结直肠癌筛查指南,本文主要针对非遗传性结直肠癌会腺瘤家族史的个体结直肠癌筛查提供指导建议。

Future Oncol:适合于东亚结直肠癌患者MSI检测位点新研究

近日,国际肿瘤期刊《Future Oncology》发表的一篇题为“The clinicopathological features and prognosis of tumor MSI in East Asian colorectal cancer patients using NCI panel”文章,通过对东亚结直肠癌(CRC)患者不同MSI检测位点进行对比,确定出最佳MSI检测Panel,

J Natl Cancer Inst:诺模图能预测晚期结直肠癌的生存率?

发表在《J Natl Cancer Inst》的一项由澳大利亚、美国、英国、德国等国学者进行的分析,使用ARCAD诺模图,考察了晚期结直肠癌患者个体化生存期的预测因素。

Liver Int:肝移植受者结直肠癌的发病率和预后:8115例患者的国家多中心分析

肝移植并不能增加结直肠癌的发病风险。原发性硬化性胆管炎/溃疡性结肠炎肝移植患者发生结直肠癌的风险明显高于一般人群,在诊断时有较高比例,的病人处于疾病晚期,病人的存活率降低。